Grant: Alliance Grants
École Polytechnique de Montréal
$217,000.00
Chitosan/Orthobiologics Biomaterials for Regenerative Medicine
EF 2024-25
Résumé
The main goal of the project is to design and create biomaterials to improve treatment of musculoskeletal
disorders, which affect 1.7 billion people globally. The Ortho-R technology, invented at Polytechnique
Montreal, was acquired in 2015 by Ortho Regenerative Technologies Inc (Ortho RTI), and the 2 entities have
since collaborated to pursue its development. A clinical study for the repair of torn tendons has begun in 2022
in the United States. R&D work is required to further advance the Ortho-R technology. The company also
wishes to explore new indications for Ortho-R and develop new biomaterials for regenerative medicine. The
targeted indications are the repair/regeneration of soft tissues (tendon, meniscus, cartilage, ligament), in order to address major medical needs that are largely unmet. The objectives of the project are A) to optimize the manufacturing processes of Ortho-R, B) to elucidate the modes of action and to characterize the structural/mechanical properties of the repair tissues obtained with Ortho-R treatment, C) to assess the potential of Ortho-R for the repair of ligaments and D) to develop new biomaterials with improved properties. This research project will generate new technologies and new intellectual property in the field of regenerative medicine.
This project will allow Ortho RTI to continue the development of Ortho-R and to develop new biomaterials
to expand its product portfolio. It will also generate new standardized mechanical tests, in addition to training
future employees of the company Biomomentum. Eventually, new know-how in biomaterial production and
analytical methods will lead to job creation at KABS Laboratories and CERASP. Around 20 highly
specialized/paid jobs in the promising field of life sciences will be created and highly qualified personnel (>35)
will be trained in a professional working/training environment. This large-scale project will make it possible to
address major medical needs that are largely unmet and will strengthen Canada's leading position in life
sciences while contributing to the country's economic growth.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
577048-2022
Name nom
Lavertu, Marc M
Department département
Génie chimique
Organization id
64
Institution établissement
École Polytechnique de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2022
Award amount
217000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
2006
Research subject group en
Materials science and technology
Research subject group fr
Science et technologie des matériaux
Research subject en
Biomaterials
Research subject fr
Biomatériaux
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Chitosan/Orthobiologics Biomaterials for Regenerative Medicine
Keywords
biomechanics; cartilage; chitosan; ligament; manufacturing scale-up; meniscus; orthobiologics; platelet-rich plasma; regenerative medicine; tendon
Application summary
The main goal of the project is to design and create biomaterials to improve treatment of musculoskeletal
disorders, which affect 1.7 billion people globally. The Ortho-R technology, invented at Polytechnique
Montreal, was acquired in 2015 by Ortho Regenerative Technologies Inc (Ortho RTI), and the 2 entities have
since collaborated to pursue its development. A clinical study for the repair of torn tendons has begun in 2022
in the United States. R&D work is required to further advance the Ortho-R technology. The company also
wishes to explore new indications for Ortho-R and develop new biomaterials for regenerative medicine. The
targeted indications are the repair/regeneration of soft tissues (tendon, meniscus, cartilage, ligament), in order to address major medical needs that are largely unmet. The objectives of the project are A) to optimize the manufacturing processes of Ortho-R, B) to elucidate the modes of action and to characterize the structural/mechanical properties of the repair tissues obtained with Ortho-R treatment, C) to assess the potential of Ortho-R for the repair of ligaments and D) to develop new biomaterials with improved properties. This research project will generate new technologies and new intellectual property in the field of regenerative medicine.
This project will allow Ortho RTI to continue the development of Ortho-R and to develop new biomaterials
to expand its product portfolio. It will also generate new standardized mechanical tests, in addition to training
future employees of the company Biomomentum. Eventually, new know-how in biomaterial production and
analytical methods will lead to job creation at KABS Laboratories and CERASP. Around 20 highly
specialized/paid jobs in the promising field of life sciences will be created and highly qualified personnel (>35)
will be trained in a professional working/training environment. This large-scale project will make it possible to
address major medical needs that are largely unmet and will strengthen Canada's leading position in life
sciences while contributing to the country's economic growth.